Kevin Nelson Quoted in Biosimilars Review and Report

Partner Kevin Nelson was quoted extensively in Stanton Mehr’s article, “Why Aren’t There More Patent Cases Pending, Considering the Size of the Biosimilar Pipeline?”  The article briefly discusses why there is a decline of BPCIA suits, and the potential impact this may have on companies and agencies.

Kevin notes, “We were seeing an uptick in biosimilar litigation and regulatory proceedings, but a number of those matters settled, and many pipeline products are the subject of settlements. The settlement landscape as a whole has ‘cleared the decks’ a bit in the short term with respect to near-term pipeline products.”

 “Manufacturers are unsure of what the exact impact of the Inflation Reduction Act will be on the payment for biosimilars,” said Mr. Nelson. “The Act purportedly seeks to keep the costs of biologic and biosimilar costs down and ensure high reimbursement payments, but many are skeptical and even believe prices will increase.”

Read the full article here.